Unknown

Dataset Information

0

Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.

ABSTRACT: Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (? = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.

SUBMITTER: Cottrell ML 

PROVIDER: S-EPMC7188232 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.

Cottrell Mackenzie L ML   Prince Heather M A HMA   Schauer Amanda P AP   Sykes Craig C   Maffuid Kaitlyn K   Poliseno Amanda A   Chun Tae-Wook TW   Huiting Erin E   Stanczyk Frank Z FZ   Peery Anne F AF   Dellon Evan S ES   Adams Jessica L JL   Gay Cindy C   Kashuba Angela D M ADM  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20191101 12

Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110. ...[more]

Similar Datasets

Unknown Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
| S-EPMC6061961 | biostudies-literature
Unknown Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
| S-EPMC7146007 | biostudies-literature
Unknown Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
| S-EPMC6330141 | biostudies-literature
Unknown Next-generation oral preexposure prophylaxis: beyond tenofovir.
| S-EPMC3732461 | biostudies-other
Unknown Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center.
| S-EPMC8496521 | biostudies-literature
Unknown Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
| S-EPMC4705855 | biostudies-other
Unknown Tenofovir-based preexposure prophylaxis for HIV infection among African women.
| S-EPMC4341965 | biostudies-literature
Unknown Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
| S-EPMC6051460 | biostudies-literature
Unknown Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents.
| S-EPMC6936000 | biostudies-literature
Unknown Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
| S-EPMC7409985 | biostudies-literature